Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02974855 · ClinicalTrials.gov registry record · Phase 2
PF-06741086 Multiple Dose Study in Severe Hemophilia
A Phase 2 study of Hemophilia A or B, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 10
- Study locations
NCT02974855 is a Phase 2 study of Hemophilia A or B that has completed, run by Pfizer. The registered enrollment target is 27 participants. The trial reports 10 study locations across 5 states.
The verdict
NCT02974855, a Phase 2 study of Hemophilia A or B, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of multiple subcutaneous and/or intravenous doses of PF-06741086 in subjects with severe hemophilia.
Conditions Studied
Interventions
- BIOLOGICAL PF-06741086
Study Locations (10)
Other
- Hospital Dr. Sotero del Rio - Santiago
- Klinicki bolnicki centar Zagreb - Zagreb
- Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne - Gdansk
- UniversitatsSpital Zurich, Klinik fur Hamatologie - Zurich
Colorado
- UC Denver Hemophilia and Thrombosis Center - Pharmacy - Aurora
- UC Denver Hemophilia and Thrombosis Center - Aurora
Illinois
- Pharmacy - Chicago
- Rush University Medical Center - Chicago
Eastern Cape
- Phoenix Pharma (Pty) Ltd - Port Elizabeth
Gauteng
- Haemophilia Comprehensive Care Centre - Johannesburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2017-03-08 |
| Est. Completion | 2018-12-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02974855
The ClinicalTrials.gov registry entry for NCT02974855 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemophilia A or B appearing as the primary indexed condition, and to 1 intervention - of which PF-06741086 is the first listed.
NCT02974855 reports 10 study locations spanning 5 distinct geographic areas - top geographies include Other, Colorado, Illinois.
Frequently Asked Questions
What is clinical trial NCT02974855 about?
NCT02974855 is a clinical study titled "PF-06741086 Multiple Dose Study in Severe Hemophilia". This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of multiple subcutaneous and/or intravenous doses of PF-06741086 in subjects with severe hemophilia.
What is the current status of trial NCT02974855?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2017-03-08. Estimated completion is 2018-12-03.
What conditions does trial NCT02974855 study?
This clinical trial studies the following conditions: Hemophilia A or B.
What interventions are being tested in trial NCT02974855?
The interventions under investigation include: PF-06741086 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02974855?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02974855 being conducted?
This trial has 10 study locations across Colorado, Illinois, Eastern Cape, Gauteng. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.